spacer
home > ict > winter 2021 > the precision paradigm
PUBLICATIONS
International Clinical Trials

The Precision Paradigm


3D bioprinting is proving to be a useful tool in healthcare research. From drug development and personalised medicine to bioengineered organs, the additive manufacturing process is enabling medical discoveries and new solutions to many of the grand challenges of our time. In areas such as cancer research and tissue regeneration, 3D bioprinting is providing the ability to research biological processes in more physiologically relevant cellular microenvironments and in specific geometrical biomimicry arrangements. This is allowing scientists to think differently when approaching biological questions, such as how to improve modelling of human diseases or how to reduce animal testing numbers. Current state-of-the-art 3D bioprinting systems are rapidly being improved upon within the community, and innovations that lie ahead may one day result in products that reach a clinic near you.

Drug Development and Personalised Medicine

The process of drug development, starting from preclinical target identification to regulatory approval for marketing, is a long journey which is often very competitive, costly, and challenging. The process demands rigorous laboratory screening of drug candidates utilising in vitro systems followed by animal testing before the promising drug candidates are tested in four phases of human clinical trials. Clinical trials are resource-intensive and can take many years at price tags as high as billions of dollars. Even if 10 viable drug candidates are identified for human trials, the majority will not make it to market. Given this high attrition rate, there is certainly an unmet need to develop improved model systems to evaluate drugs that better predict the clinical outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Erik Gatenholm is the CEO and Co-Founder of CELLINK. Erik was recently placed on MIT's Innovators Under 35 list for his achievements within life science and as an entrepreneur and has also been listed on Forbes 30 Under 30.
Print this page
Send to a friend
Privacy statement
News and Press Releases

ZEISS Integrated Workflow Solutions are Creating the Digital Transformation in Healthcare

Jena, Germany | Dublin, USA | 30 August 2022 | Carl Zeiss Meditec AC ZEISS Medical Technology continues to build on its leadership in digital solutions by exploring new ways to advance the future of transformative care in ophthalmology. At ZEISS Innovation Week, September 6-8, 2022, ZEISS Medical Technology will host leading experts in ophthalmology to share their personal experiences of how the power of integrated workflow solutions, data management and a range of new software applications are enabling improved efficiencies and optimization of patient care.
More info >>

White Papers

Detecting Integrity Breaches in a range of Pharmaceutical Blister Package Types using Sepha VisionScan

Sepha Limited

Demonstrating the integrity of pharmaceutical blister packs is critically important, as any defects can affect the shelf life and efficacy of the contents. Compared to bulk packaging, blister packs offer improved product integrity, tamper evidence and reduce the likelihood of misuse. Packs can be composed of either a thermoformed polymer or cold formed aluminium tray, with a number of individual pockets to hold the product. After the tablets or capsules are placed in the pockets, the packs are heat sealed with a paper or foil laminate sheet. These various stages can be completed separately or integrated into a single form, fill and seal process. There is a risk of microbial containment or degradation of the contents if any defects are present in the packaging. Such defects can take the form of rips or pinholes in the tray, or lid materials, faulty seals and channel leaks between pockets.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement